|Dr. Erik Manting Ph.D.||Chief Exec. Officer||N/A||N/A||1971|
|Mr. Alex Karlsson-Parra M.D., Ph.D.||Co-Founder & Chief Scientific Officer||1.42M||N/A||1950|
|Ms. Lotta Ferm||Chief Financial Officer||N/A||N/A||1966|
|Dr. Leopold Bertea Ph.D.||Chief Technology Officer||N/A||N/A||1965|
|Dr. Sven M. Rohmann M.D., MBA, Ph.D.||Bus. Devel. Advisor||N/A||N/A||1962|
|Dr. Jeroen Rovers||Chief Medical Officer||N/A||N/A||1971|
|Mr. Per-Olof Gunnesson||Advisor Contracts||N/A||N/A||1945|
Immunicum AB (publ), a biopharmaceutical company, develops immunotherapies and relapse vaccines for the treatment of cancer. Its lead product is ilixadencel, which is in Phase II MERECA clinical trial for the treatment of kidney cancer; and Phase I/II clinical trial to treat liver cancer and gastrointestinal stromal tumors. The company's products also comprise DCP-001, which is in Phase II ADVANCE-II clinical trial for the treatment of acute myeloid leukemia; and Phase I/II ALISON clinical trial for the treatment of ovarian cancers. It has a research collaboration with PCI Biotech Holding ASA for novel cancer vaccination treatment; and with Icahn School of Medicine at Mount Sinai. The company was incorporated in 2002 and is headquartered in Stockholm, Sweden.
Immunicum AB (publ)’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.